While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over-the-counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over-the-counter status where possible. In the early part of the last decade there was a decline in Rx-to-OTC switches; since 2006, however, there has been a number of uses of this tactic to extend the revenue of pharmaceutical products. In Kalorama Information's
Market for Rx to OTC Switches, we take a look at recent switches, products that may switch in the future, and categories that can benefit most from an OTC product.
The U.S. market for Rx-to-OTC switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products.
The market is fueled by several factors including an aging population; steady to increased incidences of conditions and diseases; new drug classes switched to OTC; product demand; economic conditions and several other factors.
All product areas contribute to the growth and development of the OTC market; however, new product development and additional regulatory review and approval of new OTC drug classifications, specifically in areas such as gastrointestinal drugs, cholesterol-reducing drugs, and contraceptives are expected to make the most impact for continued growth.
As part of its coverage, this report includes:
- Current Market for Rx to OTC across major categories
- Past Results of OTC Switches
- Products Most Likely to Switch to OTC
- Assessment of the Economic Situation
The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments in which Rx-to-OTC switches are available:
- Allergy, Cough, Cold, and Sinus Products
- Analgesics, NSAIDs, and Pain Treatments
- Anti-Infectives
- Gastrointestinal Drugs
- Oral Care
- Smoking Cessation
- Other Drugs, including:
- Dental Rinses and Fluorides
-
Hair Growth Products
-
Rectal Ointments
-
Sleep Aids
-
Weight Management
-
Hormone Replacement
In addition to the areas with switches in place, Kalorama Information has identified other areas which may become open to Rx-to-OTC switches in the future, including: cholesterol-reducing drugs, osteoporosis treatments, overactive bladder and sexual dysfunction. The report covers OTC drugs that were once only available by prescription due to either the active ingredient or dosage of the drug.
Current and historical revenues for product segments include both the switched brands and OTC drugs containing switched ingredients. Forecasted data includes current products and forecasted switches which are outlined in the report.
The report includes statistical information for conditions and diseases affecting the U.S. population, including detailed discussions, tables and figures. Each segment provides an overview, descriptions of products on the market, market estimates and forecasts, and competitive analysis of leading providers. In addition to above-mentioned information, the report includes current issues and trends affecting the industry and identifies trends that may arise in the future.
Trends covered in the report include:
- Healthcare Flexible Spending Accounts and OTC Medicines
- A Third Class of Drug
- Insurance Issues and Reimbursement for OTC Drugs
- Health Insurance Trends in the United States
- Impact on the Consumer
- Online Resources for Health Information
- OTC Availability
- Health Expenditures
- Pharmacists Role
- Impact on the Prescription Drug Manufacturer
- Strategies for Continued Product Growth
- Mergers and Acquisitions
- Dual Status Switching
- Generic Competition
- Direct-to-Consumer Advertising
- Patent Expiration
- Labeling Changes
- International Trends in Rx-to-OTC Switches
- Consumers around the World
- Prescription vs Over-the-Counter Industry
- World Health, Demographics and Life Expectancy
- Life Expectancy
- Birth Rates
Companies profiled in this report include:
- Bayer Healthcare
- Boehringer Ingelheim
- GlaxoSmithKline
- Johnson & Johnson
- Merck/ Schering-Plough
- Novartis
- Pfizer/Wyeth
- Procter & Gamble
- Reckitt Benckiser
- Sanofi-Aventis/Chattem
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person, email and telephone interviews were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with approximately 50 industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
